BRAF V600E and lymph node metastases in papillary thyroid cancer

Area of Science:

• Oncology
• Molecular Pathology
• Cancer Genetics

Background:

• Papillary thyroid cancer (PTC) is the most common type of thyroid malignancy.
• The BRAF V600E mutation is a key driver in PTC pathogenesis and is associated with aggressive disease.
• Understanding the role of BRAF V600E mutation in lymph node metastasis (LNM) is crucial for predicting PTC invasiveness.

Purpose of the Study:

• To investigate the association between the BRAF V600E mutation in LNM and its invasive features in PTC patients.
• To determine if the presence and characteristics of BRAF V600E mutation in LNM correlate with tumor spread and aggressiveness.

Main Methods:

• A cohort of 373 PTC patients with pathohistologically verified cervical LNM was analyzed.
• BRAF V600E mutation status was assessed in both primary tumors and LNM.
• Statistical analyses, including odds ratios and confidence intervals, were used to evaluate correlations.

Main Results:

• BRAF V600E mutation was detected in 81.5% of primary tumors and 78.0% of LNM, showing high concordance (ICC = 0.865).
• The presence of BRAF V600E mutation in both primary tumor and LNM was significantly associated with a smaller largest metastatic focus size (P < 0.001).
• No significant relationship was found between BRAF V600E mutation in LNM and the number of metastatic nodes, extranodal extension, or TNM stage (P > 0.05).

Conclusions:

• The BRAF V600E mutation in LNM of PTC is strongly concordant with its presence in primary tumors.
• While BRAF V600E mutation in LNM correlates with reduced metastatic focus size, it does not appear to be linked to other major invasive characteristics.
• Further research is needed to fully elucidate the prognostic implications of BRAF V600E mutation in PTC LNM.